Afatinib
Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors
Sold as GIOTRIF
- Drug class
- Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 10
Overview
Afatinib is an active pharmaceutical ingredient in the Epidermal Growth Factor Receptor (Egfr) Tyrosine Kinase Inhibitors group (L01EB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 9 | March 22, 2025 |
| EU European Union | EMA | 1 | May 11, 2026 |
CACanada· Health Canada
9 products
Uses
AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS ..................................................................................................... 3 WARNINGS AND PRECAUTIONS ....................................................................................
4 ADVERSE REACTIONS .................................................................................................... 10 DRUG INTERACTIONS ....................................................................................................
14 DOSAGE AND ADMINISTRATION ................................................................................ 15 OVERDOSAGE ..................................................................................................................
16 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 17 STORAGE AND STABILITY ............................................................................................ 18 SPECIAL HANDLING INSTRUCTIONS .........................................................................
EUEuropean Union· EMA
1 product
Uses
1).
How to take
Drug interactions
Known interactions involving Afatinib. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02517019 · revised March 22, 2025
- [2]European Medicines Agency · EMEA/H/C/002280 · revised May 11, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.